Mesoblast Limited (NASDAQ:MESO) is a biotechnology company developing treatments for inflammatory diseases, heart failure, ...

A downtrend has been apparent in Mesoblast Limited (MESO) lately. While the stock has lost 10.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...

Mesoblast's remestemcel (Ryoncil) is FDA-approved for steroid-refractory acute graft-versus-host disease in patients two months and older, marking a significant milestone for MSC therapies in the US.

MESO’s off-the-shelf MSC/MPC platform treats severe inflammatory diseases without donor–recipient matching. This alleviates the typical need for immunosuppression. The FDA recently approved Ryoncil, ...

A team of fintech-turned-crypto converts today launched Meso, a payment platform that brings digital assets and fiat currencies closer together, making it easier for users to move money on- and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min MESO and other small business ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more At the 2021 IEEE International Electron ...

The average one-year price target for Mesoblast Limited - Depositary Receipt (NasdaqGS:MESO) has been revised to $20.25 / share. This is an increase of 11.48% from the prior estimate of $18.16 dated ...